This study is testing a medicine called Lunsekimig for adults with moderate-to-severe asthma, a lung condition that makes breathing hard. The study compares Lunsekimig to a placebo, which is a substance with no active medicine, to see how well it works and if it's safe. Participants must be 18 to 80 years old and have had asthma for at least a year. They should already be taking certain asthma medicines called ICS (Inhaled Corticosteroids) along with one or two other medicines. People with other lung diseases like COPD (Chronic Obstructive Pulmonary Disease) or those who smoke or vape cannot join. It's also important that participants haven't had serious asthma attacks or lung infections recently. This study takes place at many sites around the world, is double-blind (neither participants nor researchers know who gets the real medicine), and randomized (participants are randomly assigned to different groups). Participants in the study will receive treatment and be monitored for safety.

• Study Duration: Participants must commit to the study duration, which may involve multiple visits.
• Eligibility: Must have moderate-to-severe asthma and meet other health criteria.
• Safety: Regular check-ups to monitor health and any side effects.